A phase II trial of first-line sorafenib in patients with metastatic renal ... - UroToday PDF Print
UroTodayOur aim was to evaluate first-line treatment of metastatic renal cell carcinoma (mRCC) with sorafenib in patients unwilling to receive immunotherapy or with

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.